Ackman: Valeant Will Not Overpay for Salix -CNBC
13 Marzo 2015 - 1:40PM
Noticias Dow Jones
Activist investor Bill Ackman, who holds a 5% stake in Valeant
Pharmaceuticals International Inc. (VRX.T), on Friday said the drug
company will not overpay in its effort to acquire Salix
Pharmaceuticals Ltd. (SLXP), despite a competing offer from Endo
International PLC.
Valeant Chief Executive J. Michael Pierson "is the most
disciplined buyer of companies. He's not going to overpay for
Salix," Mr. Ackman said in an interview on CNBC. "I don't view it
(Endo offer) as a credible bid," he said.
Web site: www.cnbc
Write to nymonitoring@dowjones.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Salix (NASDAQ:SLXP)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Salix (NASDAQ:SLXP)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024